Clinical Trial

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

Study acronym: NEXT-HF
Completed Phase 4
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-20; most recent amendment 2026-03-06.
Status change: Recruiting → Completed 2026-03-06
Trial Details
NCT Number NCT06995144
Lead Sponsor Sarfez Pharmaceuticals, Inc.
Conditions Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
Enrollment 20 participants
Start Date 2025-05-28
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-10